ADAP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.44%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $227,318.59

Adaptimmune Therapeutics Insider Trading History Chart

Adaptimmune Therapeutics Share Price & Price History

^$0.06

▼ -0.0068 (-10.51%)

As of 10/27/2025 08:59 PM ET

Days: 30 | 90 | 365

Adaptimmune Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/2/2025	Gavin Wood	CFO	Sell	96,000	$0.01	$960.00
8/28/2025	Willaim C. Bertrand, Jr.	COO	Sell	207,000	$0.01	$2,070.00	986,352
8/18/2025	Ali Behbahani	Director	Sell	14,671,794	$0.01	$146,717.94
8/15/2025	Ali Behbahani	Director	Sell	4,828,206	$0.01	$48,282.06	14,671,794
1/17/2025	Elliot Norry	Insider	Sell	5,584	$0.58	$3,238.72	7,510
1/15/2025	Cintia Piccina	Insider	Sell	12,991	$0.57	$7,404.87	18,421
1/15/2025	Willaim C. Bertrand, Jr.	COO	Sell	9,803	$0.57	$5,587.71	13,756
1/13/2025	Elliot Norry	Insider	Sell	12,392	$0.59	$7,311.28	5,845
1/13/2025	Willaim C. Bertrand, Jr.	COO	Sell	9,739	$0.59	$5,746.01	5,845
6/18/2024	Cintia Piccina	Insider	Sell	24,531	$0.93	$22,813.83	38,293
1/16/2024	Adrian Rawcliffe	CEO	Sell	9,304	$0.79	$7,350.16	14,104
1/16/2024	Elliot Norry	Insider	Sell	2,287	$0.79	$1,806.73	3,363
1/16/2024	Willaim C. Bertrand, Jr.	COO	Sell	4,681	$0.79	$3,697.99	7,023
1/12/2024	Willaim C. Bertrand, Jr.	COO	Sell	5,220	$0.85	$4,437.00	7,874
1/11/2024	Adrian Rawcliffe	CEO	Sell	11,945	$0.84	$10,033.80	18,395
1/11/2024	Elliot Norry	Insider	Sell	4,009	$0.84	$3,367.56	6,104
9/1/2023	Adrian Rawcliffe	CEO	Sell	2,403	$0.78	$1,874.34	3,449
8/1/2023	John Lunger	Insider	Sell	3,096	$0.91	$2,817.36	4,718
7/10/2023	Garry E Menzel	Director	Sell	47,702	$0.91	$43,408.82	75,056
6/27/2023	Adrian Rawcliffe	CEO	Sell	2,333	$0.92	$2,146.36	3,519
1/31/2023	Cintia Piccina	Insider	Sell	11,890	$1.87	$22,234.30	19,535
1/17/2023	Adrian Rawcliffe	CEO	Sell	10,057	$1.86	$18,706.02	13,351
1/17/2023	John Lunger	Insider	Sell	4,440	$1.86	$8,258.40	7,264
1/12/2023	Adrian Rawcliffe	CEO	Sell	18,763	$1.71	$32,084.73	24,882
1/12/2023	Willaim C. Bertrand, Jr.	COO	Sell	4,973	$1.71	$8,503.83	8,121
1/11/2023	John Lunger	Insider	Sell	3,843	$1.75	$6,725.25	6,270
1/4/2023	Adrian Rawcliffe	CEO	Sell	5,073	$1.69	$8,573.37	6,631
1/4/2023	John Lunger	Insider	Sell	1,100	$1.69	$1,859.00	1,725
1/4/2023	Willaim C. Bertrand, Jr.	COO	Sell	3,584	$1.69	$6,056.96	5,781

SEC Filings (Institutional Ownership Changes) for Adaptimmune Therapeutics (NASDAQ:ADAP)

31.37% of Adaptimmune Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Adaptimmune Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Susquehanna International Group LLP	308,065	$40K	0.0%	+491.5%	0.116%
11/17/2025	Long Focus Capital Management LLC	18,577,821	$2.42M	0.1%	-21.8%	7.009%
11/17/2025	Bank of America Corp DE	1,319,669	$0.17M	0.0%	+15.6%	0.498%
11/13/2025	UBS Group AG	6,667,358	$0.87M	0.0%	+10,490.2%	2.516%
10/31/2025	B. Riley Wealth Advisors Inc.	500,000	$65K	0.0%	N/A	0.189%
8/14/2025	MPM Bioimpact LLC	4,411,821	$1.06M	0.2%	-9.9%	1.665%
8/14/2025	MPM Asset Management LLC	4,809,677	$1.15M	2.7%	-9.9%	1.815%
8/13/2025	Two Seas Capital LP	22,580,701	$5.41M	0.1%	+10.0%	8.519%
8/11/2025	Empirical Finance LLC	800,000	$0.19M	0.0%	N/A	0.302%
7/14/2025	Clear Harbor Asset Management LLC	145,400	$35K	0.0%	-39.6%	0.055%
5/21/2025	Acadian Asset Management LLC	2,218,215	$0.42M	0.0%	+334.8%	0.862%
5/16/2025	Two Seas Capital LP	20,529,685	$4.04M	0.1%	+38.4%	7.981%
5/15/2025	MPM Bioimpact LLC	4,894,344	$0.96M	0.2%	-4.0%	1.903%
5/15/2025	MPM Asset Management LLC	5,335,715	$1.05M	1.5%	-4.0%	2.074%
5/15/2025	Long Focus Capital Management LLC	23,756,687	$4.68M	0.2%	+15.9%	9.236%
4/10/2025	Key Client Fiduciary Advisors LLC	150,150	$30K	0.0%	-41.2%	0.058%
2/18/2025	Two Seas Capital LP	14,835,146	$7.99M	0.6%	N/A	5.798%
2/17/2025	Two Sigma Investments LP	76,347	$41K	0.0%	+33.5%	0.030%
2/17/2025	Two Sigma Advisers LP	70,735	$38K	0.0%	+492.0%	0.028%
2/17/2025	Bank of America Corp DE	2,862,330	$1.54M	0.0%	-38.5%	1.119%
2/14/2025	Jane Street Group LLC	326,937	$0.18M	0.0%	+87.7%	0.128%
2/14/2025	Two Seas Capital LP	14,835,146	$7.99M	0.7%	N/A	5.798%
2/14/2025	Long Focus Capital Management LLC	20,494,393	$11.04M	0.4%	+54.1%	8.009%
2/14/2025	Rock Springs Capital Management LP	2,483,468	$1.34M	0.1%	+2.4%	0.971%
2/13/2025	Renaissance Technologies LLC	2,526,524	$1.36M	0.0%	+52.5%	0.987%
2/13/2025	Invesco Ltd.	63,335	$34K	0.0%	+82.0%	0.025%
2/12/2025	JPMorgan Chase & Co.	916,941	$0.49M	0.0%	-12.3%	0.358%
2/11/2025	LPL Financial LLC	183,479	$99K	0.0%	+106.5%	0.072%
2/11/2025	Virtu Financial LLC	122,696	$66K	0.0%	+21.5%	0.048%
1/31/2025	Baillie Gifford & Co.	11,819,095	$6.37M	0.0%	-29.5%	4.619%
11/20/2024	Virtu Financial LLC	101,008	$96K	0.0%	+27.5%	0.039%
11/15/2024	Jane Street Group LLC	174,157	$0.17M	0.0%	+130.4%	0.068%
11/15/2024	Matrix Capital Management Company LP	37,681,515	$35.81M	1.7%	-3.3%	14.734%
11/14/2024	PFM Health Sciences LP	10,000,787	$9.51M	0.5%	-4.9%	3.911%
11/13/2024	FMR LLC	1,740,900	$1.66M	0.0%	+3.0%	0.681%
11/5/2024	Baillie Gifford & Co.	16,775,860	$15.94M	0.0%	+10.7%	6.560%
11/5/2024	GSA Capital Partners LLP	99,662	$95K	0.0%	N/A	0.039%
10/29/2024	Fullcircle Wealth LLC	35,000	$33K	0.0%	N/A	0.014%
10/16/2024	Vontobel Holding Ltd.	43,000	$41K	0.0%	+230.8%	0.017%
8/15/2024	Long Focus Capital Management LLC	12,346,417	$12.04M	0.5%	+15.6%	5.002%
8/14/2024	Marshall Wace LLP	144,880	$0.14M	0.0%	-43.0%	0.059%
8/9/2024	Renaissance Technologies LLC	1,786,341	$1.74M	0.0%	+28.3%	0.724%
7/25/2024	Baillie Gifford & Co.	15,149,203	$14.77M	0.0%	-4.6%	6.138%
5/15/2024	Baker BROS. Advisors LP	10,787,022	$17.04M	0.2%	-1.7%	4.370%
5/14/2024	Boulder Hill Capital Management LP	90,800	$0.14M	0.1%	N/A	0.037%
5/3/2024	GSA Capital Partners LLP	370,179	$0.59M	0.0%	-27.2%	0.150%
5/1/2024	Baillie Gifford & Co.	15,871,875	$25.08M	0.0%	-0.3%	6.431%
4/19/2024	JTC Employer Solutions Trustee Ltd	26,156	$41K	0.0%	N/A	0.003%
4/15/2024	Key Client Fiduciary Advisors LLC	268,655	$0.42M	0.2%	-20.2%	0.027%
4/15/2024	Columbia Advisory Partners LLC	15,585	$25K	0.0%	N/A	0.002%
3/5/2024	Twin Focus Capital Partners LLC	55,526	$44K	0.0%	N/A	0.006%
1/26/2024	Baillie Gifford & Co.	15,912,140	$12.62M	0.0%	-7.2%	1.600%
1/9/2024	Key Client Fiduciary Advisors LLC	336,620	$0.27M	0.2%	+6.4%	0.034%
1/8/2024	Harbor Capital Advisors Inc.	147,732	$0.12M	0.0%	+9.9%	0.015%
11/13/2023	Baillie Gifford & Co.	17,147,409	$13.38M	0.0%	-0.2%	1.725%
10/27/2023	Marquette Asset Management LLC	99,349	$77K	0.0%	N/A	0.010%
10/27/2023	Acuitas Investments LLC	479,764	$0.37M	0.2%	N/A	0.048%
10/20/2023	Harbor Capital Advisors Inc.	134,415	$0.11M	0.0%	+19.5%	0.014%
9/21/2023	Barclays PLC	50,061	$46K	0.0%	N/A	0.005%
9/7/2023	MPM Asset Management LLC	6,287,101	$5.82M	2.9%	N/A	0.632%
8/15/2023	Black Maple Capital Management LP	69,839	$65K	0.0%	N/A	0.007%
8/14/2023	X Square Capital LLC	26,771	$25K	0.0%	N/A	0.003%
8/14/2023	CSS LLC IL	90,702	$84K	0.0%	N/A	0.009%
8/11/2023	Artal Group S.A.	1,133,775	$1.05M	0.0%	N/A	0.114%
8/7/2023	Acadian Asset Management LLC	358,010	$0.33M	0.0%	+15.1%	0.036%
8/3/2023	Oppenheimer & Co. Inc.	68,171	$63K	0.0%	N/A	0.007%
7/28/2023	Baillie Gifford & Co.	17,176,135	$15.89M	0.0%	+0.4%	1.728%
7/11/2023	Harbor Capital Advisors Inc.	112,516	$0.10M	0.0%	N/A	0.073%
5/17/2023	Long Focus Capital Management LLC	5,435,439	$5.93M	0.3%	+2.9%	3.514%
5/12/2023	Long Focus Capital Management LLC	2,772,791	$3.02M	0.3%	-47.5%	1.793%
5/10/2023	Simplify Asset Management Inc.	150,000	$0.16M	0.0%	N/A	0.097%
5/3/2023	Baillie Gifford & Co.	17,112,002	$18.65M	0.0%	-0.3%	11.064%
5/1/2023	Virtu Financial LLC	88,234	$96K	0.0%	+193.1%	0.057%
4/25/2023	Key Client Fiduciary Advisors LLC	321,155	$0.35M	0.2%	+8.2%	0.208%
2/15/2023	Endurant Capital Management LP	1,733,236	$2.53M	1.0%	-3.1%	1.058%
2/14/2023	Susquehanna International Group LLP	28,126	$41K	0.0%	N/A	0.017%
2/9/2023	HBK Sorce Advisory LLC	70,000	$65K	0.0%	+100.0%	0.043%
1/17/2023	Key Client Fiduciary Advisors LLC	296,740	$0.43M	0.3%	-31.9%	0.181%
1/11/2023	Vigilare Wealth Management	28,800	$42K	0.0%	-21.7%	0.018%
11/15/2022	PFM Health Sciences LP	9,320,584	$10.02M	0.4%	+2.3%	5.689%
11/15/2022	Long Focus Capital Management LLC	4,789,490	$5.15M	0.5%	+2.4%	2.923%
11/15/2022	Endurant Capital Management LP	1,788,517	$1.92M	0.6%	-1.9%	1.092%
11/14/2022	HBK Sorce Advisory LLC	35,000	$32K	0.0%	N/A	0.021%
11/10/2022	ExodusPoint Capital Management LP	370,288	$0.40M	0.0%	+23.4%	0.227%
11/7/2022	Virtu Financial LLC	40,503	$44K	0.0%	+133.7%	0.025%
11/3/2022	Barclays PLC	340,068	$0.37M	0.0%	+34.6%	0.208%
10/27/2022	Baillie Gifford & Co.	14,664,936	$15.76M	0.0%	-4.3%	8.977%
10/12/2022	Key Client Fiduciary Advisors LLC	435,985	$0.47M	0.4%	+4.8%	0.267%
8/12/2022	Rafferty Asset Management LLC	217,123	$0.37M	0.0%	-59.5%	0.134%
8/11/2022	Alps Advisors Inc.	96,110	$0.16M	0.0%	N/A	0.059%
8/10/2022	Hunter Associates Investment Management LLC	28,500	$49K	0.0%	+42.5%	0.018%
8/8/2022	Baillie Gifford & Co.	15,321,346	$26.05M	0.0%	-0.4%	9.457%
7/11/2022	Vigilare Wealth Management	41,800	$71K	0.1%	N/A	0.026%
5/17/2022	Endurant Capital Management LP	2,160,890	$4.45M	1.2%	+140.7%	1.335%
5/16/2022	Eversept Partners LP	237,086	$0.49M	0.0%	-32.0%	0.151%
5/11/2022	GSA Capital Partners LLP	69,612	$0.14M	0.0%	-17.3%	0.044%
5/5/2022	Baillie Gifford & Co.	15,380,538	$31.68M	0.0%	+11.8%	9.805%
5/5/2022	Levy Wealth Management Group LLC	17,590	$36K	0.0%	N/A	0.011%
4/29/2022	Daiwa Securities Group Inc.	35,516	$73K	0.0%	+44.9%	0.023%
4/26/2022	Hunter Associates Investment Management LLC	20,000	$41K	0.0%	+81.8%	0.013%

Data available starting January 2016

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $0.06

$0.05

$0.07

50 Day Range

MA: $0.09

$0.05

$0.22

52 Week Range

Now: $0.06

$0.04

$0.86

Volume

49,262,772 shs

Average Volume

127,153,136 shs

Market Capitalization

$15.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.49

Who are the company insiders with the largest holdings of Adaptimmune Therapeutics?: Adaptimmune Therapeutics' top insider shareholders include:
Ali Behbahani (Director)
William C Bertrand Jr (COO)
Cintia Piccina (Insider)
Adrian Rawcliffe (CEO)
Elliot Norry (Insider)
Gavin Wood (CFO)
Learn More about top insider investors at Adaptimmune Therapeutics.
Who are the major institutional investors of Adaptimmune Therapeutics?: Adaptimmune Therapeutics' top institutional shareholders include:
Long Focus Capital Management LLC — 7.01%
UBS Group AG — 2.52%
Bank of America Corp DE — 0.50%
B. Riley Wealth Advisors Inc. — 0.19%
Susquehanna International Group LLP — 0.12%
Citadel Advisors LLC — 0.00%
Learn More about top institutional investors of Adaptimmune Therapeutics stock.
Which institutional investors are selling Adaptimmune Therapeutics stock?: In the last quarter, ADAP stock was sold by these institutional investors:
Long Focus Capital Management LLC
During the last year, company insiders that have sold Adaptimmune Therapeutics company stock include:
Ali Behbahani (Director)
William C Bertrand Jr (COO)
Cintia Piccina (Insider)
Adrian Rawcliffe (CEO)
Elliot Norry (Insider)
Learn More investors selling Adaptimmune Therapeutics stock.
Which institutional investors are buying Adaptimmune Therapeutics stock?: During the last quarter, ADAP stock was acquired by institutional investors including:
UBS Group AG
B. Riley Wealth Advisors Inc.
Susquehanna International Group LLP
Bank of America Corp DE
Citadel Advisors LLC